Oncology and Hematology

Oncology and Hematology Clinical Practice

Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.

Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.

Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.

977

LikeLikedUnlike

226-240 of 298

Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
MinuteCE®
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
- Helena Yu, MD
- Pasi Antero Jänne, MD, PhD
0.75 program credits
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
MinuteCE®
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 program credits
MinuteCE®
HER3-Directed ADCs in the Treatment of EGFR-Mutated Advanced or Metastatic NSCLC Progressing on TKI and Platinum-Based Chemotherapy
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 credits 6 episodes
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
MinuteCE®
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
- Pasi Antero Jänne, MD, PhD
0.75 program credits
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
MinuteCE®
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 program credits
Overcoming EGFR Resistance With HER3-Directed ADCs
MinuteCE®
Overcoming EGFR Resistance With HER3-Directed ADCs
- Helena Yu, MD
0.75 program credits
advertisement
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
MinuteCE®
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
- Helena Yu, MD
- Pasi Antero Jänne, MD, PhD
0.75 program credits
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
CME/CE
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
- Brian Slomovitz, MD
- Robert L. Coleman, MD, FACOG, FACS
0.25 credits
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
CME/CE Broadcast Replay
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
- Nataliya Uboha, MD, PhD
0.75 credits
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
MinuteCE®
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credits
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
MinuteCE®
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credits
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
MinuteCE®
Clinical evidence behind emerging targeted therapy strategies in patients with metastatic NSCLC
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credits
advertisement
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
MinuteCE®
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credits
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 credits 10 episodes